$0
New Gilead KITE-222 (CLL-1 CAR-T) Ph1 Trial in R/R AML Posted
On Tuesday, March 9, a new Gilead (Kite) sponsored Ph1 trial was observed on CT.gov for a first-in-human study of KITE-222 (autologous CLL-1 CAR-T) in r/r acute myeloid leukemia (AML). Below, Celltelligence provides insights on the significance of Gilead expanding their pipeline into the AML setting and the potential competitors within the space.